Cyclic AMP raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-28. Anything still debated is marked as such rather than presented as settled.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
While Seaborg applied for funding, Harvey worked on the einsteinium target, while Thomson and Choppin focused on methods for chemical isolation. Choppin suggested using α-hydroxyisobutyric acid to separate the mendelevium atoms from those of the lighter actinides. The initial separation was done by a recoil technique suggested by Albert Ghiorso: the einsteinium was placed on the opposite side of the target from the beam, so that the momentum of the recoiling mendelevium atoms would allow them to leave the target and be caught on a gold catcher foil behind it. This recoil target was made by an electroplating technique, developed by Alfred Chetham-Strode. This technique gave a very high yield, which was absolutely necessary when working with such a rare and valuable product as the einsteinium target material. The recoil target consisted of 109 atoms of 253Es which were deposited electrolytically on a thin gold foil. It was bombarded by 41 MeV alpha particles in the Berkeley cyclotron with a very high beam density of 6×1013 particles per second over an area of 0.05 cm2. The target was cooled by water or liquid helium, and the foil could be replaced. Initial experiments were carried out in September 1954. No alpha decay was seen from mendelevium atoms; thus, Ghiorso suggested that the mendelevium had all decayed by electron capture to fermium-256, correctly believed to decay primarily by fission, and that the experiment should be repeated, this time searching for those spontaneous fission events. This version of the experiment was performed in February 1955.
For services to Education. Donna Jones. Team Leader, Ministry of Defence. For services to Defence. Janet Elizabeth Kay. Kinship Carer, Kinship. For services to Children and Families. Professor Simon Edward Kenny. National Clinical Director for Children and Young People, NHS England and Consultant Paediatric Surgeon, Alder Hey Children's Hospital. For services to Paediatric Surgery. Professor Bienvenido Arturo Langa Ferreira. Consultant Psychiatrist, NHS Lanarkshire. For services to Vulnerable People in Scotland. Nicholas David Leader. Lately Governor, HM Prison Berwyn. For Public Service. Kathryn Maria Leahy. Director of Operations, Heathrow Airport. For services to Aviation Transport and to Major Events. Cathryn Lee. Chief Executive, Alzheimer's Society. For services to Charity. Janet Legrand, KC. Lately Chair of Trustees, The Children's Society. For services to Young People. Carl Anthony Les. Leader, North Yorkshire Council. For services to Local Government. Philip John Loach, QFSM. Lately Chief Fire Officer, West Midlands Fire and Rescue Service. For services to Fire and Rescue. Dr. William Patrick James Lockhart. Deputy Director, International Biodiversity and Wildlife, Department for Environment, Food and Rural Affairs. For services to the Environment. Antony Craig Lockley. Director of Strategy and Assistant Chief Executive, Blackpool Council. For services to Local Government. Professor Mark Logan, FRSE. Chief Entrepreneurial Adviser to the Scottish Government. For services to the Economy. Sally-Ann Loudon.
Per CLIA, each specific laboratory system, assay, examination is graded for level of complexity by assigning scores of 1, 2, or 3 for each of the following seven criteria. A score of 1 is the lowest level of complexity, and a score of 3 is the highest. Score 2 is assigned when the characteristics for a particular test are intermediate between the descriptions listed for scores of 1 and 3. Criteria for categorization:
Different porphyroblasts like garnet and quartz are often formed during metamorphism in different ranges of P-T. Monazite grains are often found as inclusion in porphyroblasts. Since the host mineral monazite is quite thermally resistant, these inclusions are protected from age resetting, even with a prolonged exposure at temperature higher than 800 °C, this enables us to restrict an upper limit of the age of the porphyroblasts, and thus the associated metamorphic events. For example, a metamorphic rock in the Neil Bay area of northern Saskatchewan underwent high grade (high P/T) metamorphism followed by exhumation (uplift). The porphyroblast of garnet was formed during high grade metamorphism while the porphyroblast of cordierite was formed during subsequent exhumation. Both porphyroblasts contain monazite inclusions which were dated at 1910 Ma and 1840 Ma, respectively. And matrix monazite is dated 1800 Ma. Thus, it is interpreted that high grade metamorphism occurred after 1910 Ma and before 1840 Ma, while exhumation occurred after 1840 Ma, and the final annealing (cooling and coarsening of minerals) happened at 1800 Ma. Within the same setting as above, monazite inclusions in garnet maybe either younger than, older than or have similar ages with the matrix monazite. Both of them may even have a wide range of ages with no systematic distribution. These scenarios are interpreted to represent different metamorphic paths and conditions, giving varying or complex sequences of metamorphic reactions.
Sources: en.wikipedia.org
Recent research shows promising results in mortality and morbidity reductions when a state integrates drug monitoring programs with health information technologies and shares data through a centralized platform. The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act or the SUPPORT for Patients and Communities Act was introduced by the US House of Representatives on June 22, 2018, and was advanced on June 22, 2018. The bill includes Medicare and Medicaid reform in order to improve treatment, recovery, and prevention efforts while also strengthening the fight against synthetic drugs like fentanyl. In September 2018, the US Senate approved the SUPPORT for Patients and Communities Act (H.R. 6). The committee reached a final agreement on terms of the bill on September 25, 2018. The final agreement included provisions from multiple other acts, such as The Opioid Crisis Response Act of 2018, The Helping to End Addiction and Lessen (HEAL) Substance Use Disorders Act of 2018, and the Synthetics Trafficking and Overdose Prevention (STOP) Act of 2018. The House and The Senate passed the final draft on September 28 and October 3, respectively. President Donald Trump signed the package into law on October 28, 2018. In July 2019, English multinational consumer goods corporation Reckitt Benckiser, parent of US pharmaceutical company Indivior, agreed to pay $1.4 billion to the U.S.
=== Permanent hair reduction === Laser hair removal (lasers and laser diodes): Laser hair removal technology became widespread in the US and many other countries from the 1990s onwards. It has been approved in the United States by the FDA since 1997. With this technology, light is directed at the hair and is absorbed by dark pigment, resulting in the destruction of the hair follicle. This hair removal method sometimes becomes permanent after several sessions. The number of sessions needed depends upon the amount and type of hair being removed. Intense pulsed light (IPL) This technology is becoming more common for at-home devices, many of which are advertised as "laser hair removal" but actually use IPL technology. Diode epilation (high energy LEDs but not laser diodes)
in excess of 3 metres (9.8 feet) have been collected on several occasions, representing probable ages in excess of 400 years (Fisher, 1995). Vestimentiferan tube worm spawning is not seasonal, and recruitment is episodic. Tubeworms are either male or female. One recent discovery indicates that the spawning of female Lamellibrachia appears to have produced a unique association with the large bivalve Acesta bullisi, which lives permanently attached to the anterior tube opening of the tubeworm, and feeds on the periodic egg release (Järnegren et al., 2005). This close association between the bivalves and tubeworms was discovered in 1984 (Boland, 1986) but not fully explained. Virtually all mature Acesta individuals are found on female rather than male tubeworms. This evidence and other experiments by Järnegren et al. (2005) seem to have solved this mystery. Growth rates for methanotrophic mussels at cold seep sites have been reported (Fisher, 1995). General growth rates were found to be relatively high. Adult mussel growth rates were similar to mussels from a littoral environment at similar temperatures. Fisher also found that juvenile mussels at hydrocarbon seeps initially grow rapidly, but the growth rate drops markedly in adults; they grow to reproductive size very quickly. Both individuals and communities appear to be very long-lived. These methane-dependent mussels have strict chemical requirements that tie them to areas of the most active seepage in the Gulf of Mexico.
=== Burial in the Baháʼí Faith === In the Baháʼí Faith, burial law prescribes both the location of burial and burial practices and precludes cremation of the dead. It is forbidden to carry the body for more than one hour's journey from the place of death. Before interment the body should be wrapped in a shroud of silk or cotton, and a ring should be placed on its finger bearing the inscription "I came forth from God, and return unto Him, detached from all save Him, holding fast to His Name, the Merciful, the Compassionate". The coffin should be of crystal, stone or hard fine wood. Also, before interment, a specific Prayer for the Dead is ordained. The body should be placed with the feet facing the Qiblih. The formal prayer and the ring are meant to be used for those who have reached 15 years of age.
H-DNA motifs have been shown to stimulate homologous recombination with different mechanisms. Initial implications for the role of H-DNA in recombination came in the early 1990s when observing RecA, a bacterial DNA recombination protein composed of triple-helix DNA. RecA exhibits enzymatic activity essential for recombination. Homologous recombination involving H-DNA motifs have also been found in eukaryotes. RadA, a homologous protein to RecA, has been shown to have the same enzymatic activity in recombination as RecA. The protein has the ability to promote and exchange homologous strands through parallel triple stranded helices. The single stranded DNA (ssDNA) and complementary double stranded DNA (dsDNA) will form a D-loop structure. Another possible mechanism for RecA involves the ssDNA from two separate H-DNA structures to form Watson-Crick base pairs. The new structure is known as a Holliday junction, an intermediate in homologous recombination. H-DNA is also found in other forms of recombination. In mammalian cells, H-DNA-sequences displayed a high frequency of recombination. For example, a study conducted on myeloma cell line of mice found H-DNA structures in Cγ2a and Cγ2b, which participate in sister chromatid exchange.
Sources: en.wikipedia.org
It is responsible for growth and development of bone and muscles. The typical mutation, R202H, makes the inhibitor FKBP1A bind less tightly to the activation GS-loop. The result is that ACVR1 is not effectively turned off, and an overgrowth of bone and cartilage and fusion of joints occurs. Atypical mutations involving other residues work similarly. In some cases, the receptor can end up signalling that it's active without being bound to its activating ligand. Most cases of FOP are the result of a new gene mutation: these people had no history of this particular disorder in their family. There are some cases where the individual has inherited the mutation from one affected parent.
== Origins == Due to the long, tedious process of analyzing proteins, peptide mass fingerprinting was developed. Edman degradation was used in protein analysis, and it required almost an hour to analyze one amino acid residue. SDS-PAGE was also used to separate proteins in very complex mixtures, which also employed methods of electroblotting and staining. Then, bands would be extracted from the gel and sequenced, automatically. A recurring problem in the process was that interfering proteins would also purify with the protein of interest. The sequences of these interfering proteins were compiled into what came to known as the Dayhoff database. Ultimately, having the sequences of these known protein contaminants in databases decreased instrument time and expenses involved in protein analysis.
In July 2021, all family size limits as well as penalties for exceeding them were removed. Since abandoning population control restrictions, China has pursued pro-natalist policies in an attempt to boost the birth rate.
== Career == After her PhD, Chutia continued her research at Dibrugarh University for another year as a CSIR-postdoctoral fellow. She entered the field of plasma physics at the Physical Research Laboratory in Ahmedabad and then joined the Institute for Plasma Research in Gandhinagar. She then returned to the Institute of Advanced Study in Science and Technology as a faculty member and set up the Plasma Physics Laboratory. After finishing a fellowship awarded by the Japanese government in 1988 to work at the Plasma Laboratory of the Institute of Space and Astronautical Science, Tokyo, in 2005 she became the director of the Institute of Advanced Study in Science and Technology.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.